Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma
Clin. transl. oncol. (Print)
; 12(5): 384-386, mayo 2010. tab, ilus
Article
en En
| IBECS
| ID: ibc-124086
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy (AU)
Buscar en Google
Banco de datos:
IBECS
Asunto principal:
Enfermedad de Hodgkin
/
Activación de Linfocitos
/
Anticuerpos Monoclonales
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2010
Tipo del documento:
Article